FUNDAMENTAL AND CLINICAL STUDIES ON MT-141
スポンサーリンク
概要
- 論文の詳細を見る
Fundamental and clinical studies were carried out on MT-141, and the following results were obtained.<BR>1) Fundamental study: Rats were employed to investigate the transfer of MT-141 to the bronchoalveolar spaces. The bronchoalveoli were washed, and the concentration of MT-141 in the collected wash solution was determined. A comparison was made with the case of CEZ.<BR>In the case of i. m. administration of the drugs at 100 mg/kg, both MT-141 and CEZ showed high recovery amounts at 0.5hr. The recovery of CEZ, however, was slightly superior. At 1hour after dosing, the amount of CEZ recovered decreased suddenly, becoming about 1/2 that of MT-141. At 2hr after dosing, the amount of both drugs recovered had decreased to only traces. When the administered dose was 20mg/kg, both MT-141 and CEZ could be recovered in only trace amounts.<BR>2) Clinical study: MT-141 was administered as therapy to 7 patients diagnosed as having the following infections: 4 cases of pneumonia, and one case each of acute bronchitis, diffuse panbronchiolitis and acute urinary tract infection. These patients consisted of 6 males and one female, and they ranged in age from 38 to 73 years (mean age: 62 years). The daily dosage of MT-141 was 1g in 3 patients and 2g in 4patients, divided into a morning dose and an evening dose. The MT-141 therapy was continued for 7-15 days (mean duration: 11days), and the total dosage thus ranged from 14g to 28g (mean: 17.3g). The clinical efficacy was evaluated as "excellent" in one case, "good" in 5cases, and "poor" in one case. The "good" or greater efficacy rate was thus 85.7%.<BR>The causative bacterium was able to be identified in 2 of the patients. In the patient with diffuse panbronchiolitis, <I>Acinetobacter</I> was isolated, and then this was found to be replaced by <I>P. aeruginosa</I>; nevertheless, the MT-141 therapy was clinically effective in this patient. In the patient with diffuse panbronchiolitis, <I>Acinetobacter</I> was isolated, and then this was found to be replaced by <I>P. aeruginosa</I>; nevertheless, the MT-141 therapy was clinically effective in this patient. <I>E. coli</I> was isolated from the patient with an acute urinary tract infection, and the therapy was clinically effective in this case, with the bacterium being eliminated. No particular adverse experiences or abnormal laboratory test values were recorded, with the exception of one patient showing eosinophilia.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.